End-of-day quote
Taipei Exchange
23:00:00 14/05/2024 BST
|
5-day change
|
1st Jan Change
|
19.8
TWD
|
+1.02%
|
|
-1.98%
|
-26.67%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
470.9
|
455.5
|
3,231
|
2,082
|
1,609
|
1,615
|
Enterprise Value (EV)
1 |
490.7
|
550.5
|
2,822
|
2,163
|
1,727
|
1,947
|
P/E ratio
|
-6.69
x
|
-11.5
x
|
45.8
x
|
47.2
x
|
-30.2
x
|
-8.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.93
x
|
1.9
x
|
6.79
x
|
3.77
x
|
4.34
x
|
6.1
x
|
EV / Revenue
|
2.01
x
|
2.3
x
|
5.93
x
|
3.92
x
|
4.66
x
|
7.35
x
|
EV / EBITDA
|
-11.4
x
|
-36.5
x
|
44.5
x
|
33.3
x
|
-76.1
x
|
-14.6
x
|
EV / FCF
|
-17.3
x
|
65.4
x
|
1,440
x
|
79.2
x
|
-5.92
x
|
6.67
x
|
FCF Yield
|
-5.77%
|
1.53%
|
0.07%
|
1.26%
|
-16.9%
|
15%
|
Price to Book
|
4.71
x
|
6.33
x
|
4.72
x
|
2.85
x
|
2.33
x
|
3.27
x
|
Nbr of stocks (in thousands)
|
38,886
|
39,886
|
59,824
|
59,824
|
59,824
|
59,824
|
Reference price
2 |
12.11
|
11.42
|
54.00
|
34.80
|
26.90
|
27.00
|
Announcement Date
|
30/04/19
|
30/04/20
|
29/04/21
|
27/04/22
|
28/04/23
|
30/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
243.8
|
239.7
|
475.9
|
551.7
|
370.5
|
264.8
|
EBITDA
1 |
-43.09
|
-15.08
|
63.47
|
64.95
|
-22.69
|
-133.3
|
EBIT
1 |
-63.01
|
-34.54
|
43.37
|
43.79
|
-40.87
|
-169.9
|
Operating Margin
|
-25.84%
|
-14.41%
|
9.11%
|
7.94%
|
-11.03%
|
-64.17%
|
Earnings before Tax (EBT)
1 |
-68.73
|
-39.05
|
48.29
|
38.61
|
-46.13
|
-187.7
|
Net income
1 |
-69.22
|
-39.05
|
62.15
|
44.14
|
-53.19
|
-198.8
|
Net margin
|
-28.39%
|
-16.29%
|
13.06%
|
8%
|
-14.36%
|
-75.08%
|
EPS
2 |
-1.810
|
-0.9891
|
1.178
|
0.7379
|
-0.8900
|
-3.320
|
Free Cash Flow
1 |
-28.33
|
8.424
|
1.959
|
27.32
|
-291.8
|
291.7
|
FCF margin
|
-11.62%
|
3.52%
|
0.41%
|
4.95%
|
-78.77%
|
110.16%
|
FCF Conversion (EBITDA)
|
-
|
-
|
3.09%
|
42.06%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
3.15%
|
61.89%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/04/19
|
30/04/20
|
29/04/21
|
27/04/22
|
28/04/23
|
30/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
19.8
|
95.1
|
-
|
80.7
|
118
|
331
|
Net Cash position
1 |
-
|
-
|
409
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.4584
x
|
-6.304
x
|
-
|
1.242
x
|
-5.19
x
|
-2.486
x
|
Free Cash Flow
1 |
-28.3
|
8.42
|
1.96
|
27.3
|
-292
|
292
|
ROE (net income / shareholders' equity)
|
-52.5%
|
-45.5%
|
16.3%
|
6.2%
|
-7.54%
|
-33.6%
|
ROA (Net income/ Total Assets)
|
-12.9%
|
-7.66%
|
4.86%
|
2.61%
|
-1.81%
|
-5.2%
|
Assets
1 |
535.5
|
509.7
|
1,278
|
1,692
|
2,931
|
3,826
|
Book Value Per Share
2 |
2.570
|
1.800
|
11.40
|
12.20
|
11.50
|
8.260
|
Cash Flow per Share
2 |
0.9400
|
0.5700
|
5.860
|
5.160
|
4.380
|
3.620
|
Capex
1 |
20.3
|
1.15
|
23.3
|
14.7
|
248
|
424
|
Capex / Sales
|
8.31%
|
0.48%
|
4.89%
|
2.67%
|
67.06%
|
160.11%
|
Announcement Date
|
30/04/19
|
30/04/20
|
29/04/21
|
27/04/22
|
28/04/23
|
30/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -26.67% | 36.24M | | -4.62% | 12.18B | | +8.48% | 5.96B | | +28.39% | 5.45B | | -6.28% | 4.34B | | -52.84% | 3.18B | | +12.93% | 2.75B | | +28.84% | 2.3B | | -3.80% | 2.28B | | -4.64% | 1.92B |
Diagnostic & Testing Substances
|